In a recent company press release, Bristol-Myers Squibb has announced the appointment of Mike Burgess as Senior Vice President of their Discovery Medicine and Clinical Pharmacology department.
Burgess, a member of the Royal College of Physicians and the Royal College of Pediatrics and Child Health, studied for both his medical training and PhD at Bristol University (UK). He has since worked at Eli Lilly and Hoffman La-Roche. Directly prior to this appointment saw him as head of Hoffman La-Roche’s Pharmaceutical Research and Early Development organization.
Burgess will report to Senior Vice President for Research, R&D, Francis Cuss. Commenting on the appointment, Cuss stated, “As a physician scientist with a PhD in molecular biology, clinical experience in pediatrics and pediatric oncology, and extensive pharmaceutical industry and leadership experience, I believe Mike will be an important addition to our research and development organization. Mike’s broad clinical expertise, cross-therapeutic global team leadership and proven operational excellence will enable Bristol-Myers Squibb to continue to execute its strategy of ensuring sustainable delivery of an innovative pipeline of new medicines for patients.”
Burgess expressed his excitement at this opportunity, “Bristol-Myers Squibb is well known and respected for its innovative pipeline and approach to discovering and developing new medicines. I am looking forward to joining this committed team and continuing to drive research that delivers a differentiated pipeline of potential new medicines.”